Cargando…

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial

BACKGROUND: Liraglutide is an antidiabetic agent with cardioprotective effect. The purpose of this study is to test efficacy of liraglutide to improve diabetic cardiomyopathy in patients with diabetes mellitus type 2 (DM2) without cardiovascular disease. METHODS: Patients with DM2 were randomly assi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bizino, Maurice B., Jazet, Ingrid M., Westenberg, Jos J. M., van Eyk, Huub J., Paiman, Elisabeth H. M., Smit, Jan W. A., Lamb, Hildebrandus J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492440/
https://www.ncbi.nlm.nih.gov/pubmed/31039778
http://dx.doi.org/10.1186/s12933-019-0857-6
_version_ 1783415147245600768
author Bizino, Maurice B.
Jazet, Ingrid M.
Westenberg, Jos J. M.
van Eyk, Huub J.
Paiman, Elisabeth H. M.
Smit, Jan W. A.
Lamb, Hildebrandus J.
author_facet Bizino, Maurice B.
Jazet, Ingrid M.
Westenberg, Jos J. M.
van Eyk, Huub J.
Paiman, Elisabeth H. M.
Smit, Jan W. A.
Lamb, Hildebrandus J.
author_sort Bizino, Maurice B.
collection PubMed
description BACKGROUND: Liraglutide is an antidiabetic agent with cardioprotective effect. The purpose of this study is to test efficacy of liraglutide to improve diabetic cardiomyopathy in patients with diabetes mellitus type 2 (DM2) without cardiovascular disease. METHODS: Patients with DM2 were randomly assigned to receive liraglutide 1.8 mg/day or placebo in this double-blind trial of 26 weeks. Primary outcome measures were LV diastolic function (early (E) and late (A) transmitral peak flow rate, E/A ratio, early deceleration peak (Edec), early peak mitral annular septal tissue velocity (Ea) and estimated LV filling pressure (E/Ea), and systolic function (stroke volume, ejection fraction, cardiac output, cardiac index and peak ejection rate) assessed with CMR. Intention-to-treat analysis of between-group differences was performed using ANCOVA. Mean estimated treatment differences (95% confidence intervals) are reported. RESULTS: 23 patients were randomized to liraglutide and 26 to placebo. As compared with placebo, liraglutide significantly reduced E (− 56 mL/s (− 91 to − 21)), E/A ratio (− 0.17 (− 0.27 to − 0.06)), Edec (− 0.9 mL/s(2) * 10(−3) (− 1.3 to − 0.2)) and E/Ea (− 1.8 (− 3.0 to − 0.6)), without affecting A (3 mL/s (− 35 to 41)) and Ea (0.4 cm/s (− 0.9 to 1.4)). Liraglutide reduced stroke volume (− 9 mL (− 16 to − 2)) and ejection fraction (− 3% (− 6 to − 0.1)), but did not change cardiac output (− 0.4 L/min (− 0.9 to 0.2)), cardiac index (− 0.1 L/min/m(2) (− 0.4 to 0.1)) and peak ejection rate (− 46 mL/s (− 95 to 3)). CONCLUSIONS: Liraglutide reduced early LV diastolic filling and LV filling pressure, thereby unloading the left ventricle. LV systolic function reduced and remained within normal range. Future studies are needed to investigate if liraglutide-induced left ventricular unloading slows progression of diabetic cardiomyopathy into symptomatic stages. Trial registration ClinicalTrials.gov: NCT01761318.
format Online
Article
Text
id pubmed-6492440
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64924402019-05-08 Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial Bizino, Maurice B. Jazet, Ingrid M. Westenberg, Jos J. M. van Eyk, Huub J. Paiman, Elisabeth H. M. Smit, Jan W. A. Lamb, Hildebrandus J. Cardiovasc Diabetol Original Investigation BACKGROUND: Liraglutide is an antidiabetic agent with cardioprotective effect. The purpose of this study is to test efficacy of liraglutide to improve diabetic cardiomyopathy in patients with diabetes mellitus type 2 (DM2) without cardiovascular disease. METHODS: Patients with DM2 were randomly assigned to receive liraglutide 1.8 mg/day or placebo in this double-blind trial of 26 weeks. Primary outcome measures were LV diastolic function (early (E) and late (A) transmitral peak flow rate, E/A ratio, early deceleration peak (Edec), early peak mitral annular septal tissue velocity (Ea) and estimated LV filling pressure (E/Ea), and systolic function (stroke volume, ejection fraction, cardiac output, cardiac index and peak ejection rate) assessed with CMR. Intention-to-treat analysis of between-group differences was performed using ANCOVA. Mean estimated treatment differences (95% confidence intervals) are reported. RESULTS: 23 patients were randomized to liraglutide and 26 to placebo. As compared with placebo, liraglutide significantly reduced E (− 56 mL/s (− 91 to − 21)), E/A ratio (− 0.17 (− 0.27 to − 0.06)), Edec (− 0.9 mL/s(2) * 10(−3) (− 1.3 to − 0.2)) and E/Ea (− 1.8 (− 3.0 to − 0.6)), without affecting A (3 mL/s (− 35 to 41)) and Ea (0.4 cm/s (− 0.9 to 1.4)). Liraglutide reduced stroke volume (− 9 mL (− 16 to − 2)) and ejection fraction (− 3% (− 6 to − 0.1)), but did not change cardiac output (− 0.4 L/min (− 0.9 to 0.2)), cardiac index (− 0.1 L/min/m(2) (− 0.4 to 0.1)) and peak ejection rate (− 46 mL/s (− 95 to 3)). CONCLUSIONS: Liraglutide reduced early LV diastolic filling and LV filling pressure, thereby unloading the left ventricle. LV systolic function reduced and remained within normal range. Future studies are needed to investigate if liraglutide-induced left ventricular unloading slows progression of diabetic cardiomyopathy into symptomatic stages. Trial registration ClinicalTrials.gov: NCT01761318. BioMed Central 2019-04-30 /pmc/articles/PMC6492440/ /pubmed/31039778 http://dx.doi.org/10.1186/s12933-019-0857-6 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Bizino, Maurice B.
Jazet, Ingrid M.
Westenberg, Jos J. M.
van Eyk, Huub J.
Paiman, Elisabeth H. M.
Smit, Jan W. A.
Lamb, Hildebrandus J.
Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
title Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
title_full Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
title_fullStr Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
title_full_unstemmed Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
title_short Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
title_sort effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492440/
https://www.ncbi.nlm.nih.gov/pubmed/31039778
http://dx.doi.org/10.1186/s12933-019-0857-6
work_keys_str_mv AT bizinomauriceb effectofliraglutideoncardiacfunctioninpatientswithtype2diabetesmellitusrandomizedplacebocontrolledtrial
AT jazetingridm effectofliraglutideoncardiacfunctioninpatientswithtype2diabetesmellitusrandomizedplacebocontrolledtrial
AT westenbergjosjm effectofliraglutideoncardiacfunctioninpatientswithtype2diabetesmellitusrandomizedplacebocontrolledtrial
AT vaneykhuubj effectofliraglutideoncardiacfunctioninpatientswithtype2diabetesmellitusrandomizedplacebocontrolledtrial
AT paimanelisabethhm effectofliraglutideoncardiacfunctioninpatientswithtype2diabetesmellitusrandomizedplacebocontrolledtrial
AT smitjanwa effectofliraglutideoncardiacfunctioninpatientswithtype2diabetesmellitusrandomizedplacebocontrolledtrial
AT lambhildebrandusj effectofliraglutideoncardiacfunctioninpatientswithtype2diabetesmellitusrandomizedplacebocontrolledtrial